LAMEA Myasthenia Gravis Treatment Market Size, Share & Industry Trends Analysis Report By End-use (Hospitals, Clinics and Others), By Type, By Country and Growth Forecast, 2023 - 2030

The Latin America, Middle East and Africa Myasthenia Gravis Treatment Market would witness market growth of 12.2% CAGR during the forecast period (2023-2030).

Physicians are increasingly exploring combination therapy strategies that involve the concurrent use of different medications to manage MG symptoms effectively. This approach can lead to enhanced symptom control and improved patient outcomes. The adoption of telemedicine and remote patient support services is on the rise, enabling consultations, monitoring, and guidance for individuals managing MG. These digital platforms provide accessible and convenient avenues for patient care. Ongoing research is focused on identifying novel therapeutic targets in the management of MG.

Developing monoclonal antibodies that target specific immune pathways involved in MG is a significant innovation. These antibodies aim to provide more precise and effective immune modulation, potentially reducing the need for broad immunosuppression. Research efforts are ongoing to develop treatments that are not only more effective but also safer, with fewer side effects. This innovation focuses on improving the risk-benefit profile of MG treatments. Innovations in immune modulation therapies aim to provide more targeted approaches, minimizing harm to healthy immune function while suppressing the pathogenic immune response.

Many countries within the LAMEA region have been focusing on improving their healthcare infrastructure by investing in hospitals, clinics, and healthcare programs to provide better services to their citizens. As per the data published in 2023 by the International Trade Administration, South Africa's healthcare system is divided into two parts: the public system, which serves approximately 85 percent of the population and accounts for roughly 48 percent of total healthcare expenditure with state support (nearly 9 percent of GDP). Therefore, the rising healthcare sector in many countries of the LAMEA region will boost the demand for myasthenia gravis treatments in the region.

The Brazil market dominated the LAMEA Myasthenia Gravis Treatment Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $48 Million by 2030. The Argentina market is showcasing a CAGR of 12.8% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 11.8% during (2023 - 2030).

Based on End-use, the market is segmented into Hospitals, Clinics and Others. Based on Type, the market is segmented into Monoclonal Antibodies, Thymectomy, Cholinesterase Inhibitors, Chronic Immunomodulators, Rapid Immunotherapies and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

Free Valuable Insights: The Worldwide Myasthenia Gravis Treatment Market is Projected to reach USD 3.8 Billion by 2030, at a CAGR of 9.2%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca PLC (Alexion Pharmaceuticals, Inc.), Octapharma AG, Novartis AG, Pfizer, Inc., Allergan PLC (AbbVie, Inc.), F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Bausch Health Companies Inc., Kedrion S.p.A, and Zydus Lifesciences Ltd.

Scope of the Study

Market Segments Covered in the Report:

By End-use

• Hospitals
• Clinics
• Others

By Type

• Monoclonal Antibodies
• Thymectomy
• Cholinesterase Inhibitors
• Chronic Immunomodulators
• Rapid Immunotherapies
• Others

By Country

• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

• AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
• Octapharma AG
• Novartis AG
• Pfizer, Inc.
• Allergan PLC (AbbVie, Inc.)
• F.Hoffmann-La Roche Ltd.
• GlaxoSmithKline PLC (GSK)
• Bausch Health Companies Inc.
• Kedrion S.p.A
• Zydus Lifesciences Ltd.

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Myasthenia Gravis Treatment Market, by End-use
1.4.2 LAMEA Myasthenia Gravis Treatment Market, by Type
1.4.3 LAMEA Myasthenia Gravis Treatment Market, by Country
1.5 Methodology for the research

Chapter 2. Market at a Glance
2.1 Key Highlights

Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter Five Forces Analysis

Chapter 4. LAMEA Myasthenia Gravis Treatment Market by End-use
4.1 LAMEA Hospitals Market by Country
4.2 LAMEA Clinics Market by Country
4.3 LAMEA Others Market by Country

Chapter 5. LAMEA Myasthenia Gravis Treatment Market by Type
5.1 LAMEA Monoclonal Antibodies Market by Country
5.2 LAMEA Thymectomy Market by Country
5.3 LAMEA Cholinesterase Inhibitors Market by Country
5.4 LAMEA Chronic Immunomodulators Market by Country
5.5 LAMEA Rapid Immunotherapies Market by Country
5.6 LAMEA Others Market by Country

Chapter 6. LAMEA Myasthenia Gravis Treatment Market by Country
6.1 Brazil Myasthenia Gravis Treatment Market
6.1.1 Brazil Myasthenia Gravis Treatment Market by End-use
6.1.2 Brazil Myasthenia Gravis Treatment Market by Type
6.2 Argentina Myasthenia Gravis Treatment Market
6.2.1 Argentina Myasthenia Gravis Treatment Market by End-use
6.2.2 Argentina Myasthenia Gravis Treatment Market by Type
6.3 UAE Myasthenia Gravis Treatment Market
6.3.1 UAE Myasthenia Gravis Treatment Market by End-use
6.3.2 UAE Myasthenia Gravis Treatment Market by Type
6.4 Saudi Arabia Myasthenia Gravis Treatment Market
6.4.1 Saudi Arabia Myasthenia Gravis Treatment Market by End-use
6.4.2 Saudi Arabia Myasthenia Gravis Treatment Market by Type
6.5 South Africa Myasthenia Gravis Treatment Market
6.5.1 South Africa Myasthenia Gravis Treatment Market by End-use
6.5.2 South Africa Myasthenia Gravis Treatment Market by Type
6.6 Nigeria Myasthenia Gravis Treatment Market
6.6.1 Nigeria Myasthenia Gravis Treatment Market by End-use
6.6.2 Nigeria Myasthenia Gravis Treatment Market by Type
6.7 Rest of LAMEA Myasthenia Gravis Treatment Market
6.7.1 Rest of LAMEA Myasthenia Gravis Treatment Market by End-use
6.7.2 Rest of LAMEA Myasthenia Gravis Treatment Market by Type

Chapter 7. Company Profiles
7.1 AstraZeneca PLC (Alexion Pharmaceuticals, Inc.)
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Approval and Trails:
7.1.6 SWOT Analysis
7.2 Octapharma AG
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Research & Development Expenses
7.3 Novartis AG
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.3.5 SWOT Analysis
7.4 Pfizer, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional & Segmental Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Approval and Trails:
7.4.6 SWOT Analysis
7.5 Allergan PLC (AbbVie, Inc.)
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.1 Research & Development Expense
7.5.2 SWOT Analysis
7.6 F. Hoffmann-La Roche Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 SWOT Analysis
7.7 GlaxoSmithKline PLC (GSK)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.7.5 SWOT Analysis
7.8 Bausch Health Companies Inc
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expenses
7.8.5 SWOT Analysis
7.9 Kedrion S.p.A
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Research & Development Expenses
7.9.4 SWOT Analysis
7.10. Zydus Lifesciences Ltd.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 SWOT Analysis

TABLE 1 LAMEA Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 2 LAMEA Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 3 LAMEA Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 4 LAMEA Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 5 LAMEA Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 6 LAMEA Hospitals Market by Country, 2023 - 2030, USD Million
TABLE 7 LAMEA Clinics Market by Country, 2019 - 2022, USD Million
TABLE 8 LAMEA Clinics Market by Country, 2023 - 2030, USD Million
TABLE 9 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 10 LAMEA Others Market by Country, 2023 - 2030, USD Million
TABLE 11 LAMEA Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 12 LAMEA Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 13 LAMEA Monoclonal Antibodies Market by Country, 2019 - 2022, USD Million
TABLE 14 LAMEA Monoclonal Antibodies Market by Country, 2023 - 2030, USD Million
TABLE 15 LAMEA Thymectomy Market by Country, 2019 - 2022, USD Million
TABLE 16 LAMEA Thymectomy Market by Country, 2023 - 2030, USD Million
TABLE 17 LAMEA Cholinesterase Inhibitors Market by Country, 2019 - 2022, USD Million
TABLE 18 LAMEA Cholinesterase Inhibitors Market by Country, 2023 - 2030, USD Million
TABLE 19 LAMEA Chronic Immunomodulators Market by Country, 2019 - 2022, USD Million
TABLE 20 LAMEA Chronic Immunomodulators Market by Country, 2023 - 2030, USD Million
TABLE 21 LAMEA Rapid Immunotherapies Market by Country, 2019 - 2022, USD Million
TABLE 22 LAMEA Rapid Immunotherapies Market by Country, 2023 - 2030, USD Million
TABLE 23 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 24 LAMEA Others Market by Country, 2023 - 2030, USD Million
TABLE 25 LAMEA Myasthenia Gravis Treatment Market by Country, 2019 - 2022, USD Million
TABLE 26 LAMEA Myasthenia Gravis Treatment Market by Country, 2023 - 2030, USD Million
TABLE 27 Brazil Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 28 Brazil Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 29 Brazil Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 30 Brazil Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 31 Brazil Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 32 Brazil Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 33 Argentina Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 34 Argentina Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 35 Argentina Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 36 Argentina Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 37 Argentina Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 38 Argentina Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 39 UAE Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 40 UAE Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 41 UAE Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 42 UAE Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 43 UAE Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 44 UAE Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 45 Saudi Arabia Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 46 Saudi Arabia Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 47 Saudi Arabia Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 48 Saudi Arabia Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 49 Saudi Arabia Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 50 Saudi Arabia Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 51 South Africa Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 52 South Africa Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 53 South Africa Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 54 South Africa Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 55 South Africa Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 56 South Africa Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 57 Nigeria Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 58 Nigeria Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 59 Nigeria Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 60 Nigeria Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 61 Nigeria Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 62 Nigeria Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 63 Rest of LAMEA Myasthenia Gravis Treatment Market, 2019 - 2022, USD Million
TABLE 64 Rest of LAMEA Myasthenia Gravis Treatment Market, 2023 - 2030, USD Million
TABLE 65 Rest of LAMEA Myasthenia Gravis Treatment Market by End-use, 2019 - 2022, USD Million
TABLE 66 Rest of LAMEA Myasthenia Gravis Treatment Market by End-use, 2023 - 2030, USD Million
TABLE 67 Rest of LAMEA Myasthenia Gravis Treatment Market by Type, 2019 - 2022, USD Million
TABLE 68 Rest of LAMEA Myasthenia Gravis Treatment Market by Type, 2023 - 2030, USD Million
TABLE 69 KEY INFORMATION – ASTRAZENECA PLC
TABLE 70 Key Information – Octapharma AG
TABLE 71 Key Information – Novartis AG
TABLE 72 Key Information – Pfizer, Inc.
TABLE 73 Key Information – Allergan PLC
TABLE 74 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 75 Key Information – GlaxoSmithKline PLC
TABLE 76 Key Information – Bausch Health Companies Inc
TABLE 77 key Information – Kedrion S.p.A
TABLE 78 Key Information – Zydus Lifesciences Ltd.

List of Figures
FIG 1 Methodology for the research
FIG 2 LAMEA Myasthenia Gravis Treatment Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Myasthenia Gravis Treatment Market
FIG 4 Porter’s Five Forces Analysis – Myasthenia Gravis Treatment Market
FIG 5 LAMEA Myasthenia Gravis Treatment Market share by End-use, 2022
FIG 6 LAMEA Myasthenia Gravis Treatment Market share by End-use, 2030
FIG 7 LAMEA Myasthenia Gravis Treatment Market by End-use, 2019 - 2030, USD Million
FIG 8 LAMEA Myasthenia Gravis Treatment Market share by Type, 2022
FIG 9 LAMEA Myasthenia Gravis Treatment Market share by Type, 2030
FIG 10 LAMEA Myasthenia Gravis Treatment Market by Type, 2019 - 2030, USD Million
FIG 11 LAMEA Myasthenia Gravis Treatment Market share by Country, 2022
FIG 12 LAMEA Myasthenia Gravis Treatment Market share by Country, 2030
FIG 13 LAMEA Myasthenia Gravis Treatment Market by Country, 2019 - 2030, USD Million
FIG 14 SWOT Analysis: AstraZeneca PLC
FIG 15 SWOT Analysis: Novartis AG
FIG 16 SWOT Analysis: Pfizer, Inc.
FIG 17 SWOT Analysis: Allergan PLC
FIG 18 Swot Analysis: F. Hoffmann-La Roche Ltd.
FIG 19 SWOT Analysis: GlaxoSmithKline PLC
FIG 20 SWOT Analysis: Bausch Health Companies Inc
FIG 21 SWOT Analysis: Kedrion S.p.A
FIG 22 SWOT Analysis: Zydus Lifesciences Ltd.